84 results on '"Tyldesley S"'
Search Results
2. Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial
3. Polymetastatic Recurrence-Free Survival in Patients with Repeat Oligometastases on the SABR-5 Trial
4. Prospective Longitudinal Assessment of Quality of Life after Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-Based SABR-5 Phase II Trial
5. OC-0268 Should OARs be prioritized in SABR for oligometastases? A secondary analysis of the SABR-5 trial
6. Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial
7. Impact of Quality Assurance and Feedback on Radiotherapy Prescribing Practices: A Randomized Controlled Trial
8. First Pan-Canadian Consensus Recommendations for Proton Beam Therapy Access in Canada
9. Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR): Overall Survival Results of the SABR-5 Trial
10. PO-1031 Canadian Radiation Oncology 2020 Work Engagement and Burnout Survey
11. Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for up to 5 Oligometastases: Preliminary Results of the SABR-5 Trial
12. PO-1205: Small cell carcinoma of the bladder: Retrospective long-term outcomes of chemoradiation
13. Stereotactic Ablative Radiotherapy (SABR) For Oligometastases: Risk Stratification Using Positional Uncertainty
14. An Updated Analysis of Survival Endpoints for ASCENDE-RT, a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
15. In the Era After the European Organisation for Research and Treatment of Cancer ‘Boost’ Study, is the Additional Radiotherapy to the Breast Tumour Bed Still Beneficial for Young Women?
16. EP-1616 Population-based Phase II Trial of Stereotactic Radiotherapy for up to 5 Oligometastases: SABR-5
17. Pathologically Node-Positive Prostate Carcinoma – Prevalence, Pattern of Care and Outcome From a Population-Based Study
18. Cancer-Specific Outcomes of Hypofractionated Locoregional Radiation Therapy for Patients with Stage I-III Breast Cancer
19. The Use of Chemotherapy Instead of Radiation Therapy Does Not Reduce the Incidence of Second Cancers in Survivors of Early Stage Seminoma: A Population-Based Study from British Columbia
20. Mapping Patterns of Regional Nodal Recurrence After Treatment in Breast Cancer Patients: Evaluation of the RTOG Breast Cancer Atlas
21. The Relationship between Hot Flashes and Testosterone Recovery after 12 Months of Androgen Suppression for Men with Localised Prostate Cancer in the ASCENDE-RT Trial
22. EP-1195: Regional nodal recurrences after adjuvant breast radiotherapy - are we covering the target?
23. EP-1359: Pain response in a Population-based study of Radium-223 for Metastatic Prostate Cancer
24. An Evaluation Of Competing Causes Of Death in Patients Treated for Seminoma With Radiation Therapy.
25. Do Young Women Benefit From a Radiation Therapy Boost to the Tumor Bed in the Hormone Therapy Era?
26. Impact of Internal Mammary Node Radiation on Survival of Patients With Breast Cancer: Extended Follow-Up of a Population-Based Analysis
27. The Relationship Between Hot Flashes and Testosterone Recovery Following 12 Months of Androgen Suppression for Men With Localized Prostate Cancer in a Randomized Trial
28. Do Women Who Died of Cardiac Disease Within 10 Years of Breast or Chest Wall Radiation Therapy Violate the “QUANTEC” Cardiac Dose-Volume Histogram Guidelines?
29. Toxicity Outcomes in ASCENDE-RT: A Multicenter Randomized Trial of Dose-Escalation Trial for Prostate Cancer
30. Low-Dose-Rate Prostate Brachytherapy Is Superior to Dose-Escalated EBRT for Unfavorable Risk Prostate Cancer: The Results of the ASCENDE-RT Randomized Control Trial
31. Population-based analysis of the impact and generalizability of the NSABP-B24 study on endocrine therapy for patients with ductal carcinoma in situ of the breast
32. PD-0047: GU and GI toxicity in ASCENDE-RT*: a multicentre randomized trial of dose-escalated radiation for prostate cancer
33. EP-1186: Neoadjuvant systemic therapy utilization in breast cancer; potential impact on nodal radiotherapy
34. OC-0485: LDR brachytherapy is superior to 78 Gy of EBRT for unfavourable risk prostate cancer: the results of a randomized trial
35. HOSPITAL-RELATED CARDIAC MORBIDITY AMONG SURVIVORS OF BREAST CANCER: LONG-TERM RISKS AND PREDICTORS
36. A National Survey on Peer Review: Canadian Radiation Oncologists’ Views Regarding the Benefits, Practical Workload Implications, and Legal Liability
37. The Incidence of Second Malignancies Following Low-Dose-Rate Brachytherapy for Prostate Cancer
38. Population-Based Analysis of the Impact and Generalizability of the Nsabp B24 Study on Endocrine Therapy (ET) for Ductal Carcinoma in Situ (DCIS) of the Breast
39. Second Malignancies after Adjuvant Radiotherapy for Early Stage Breast Cancer: Is There an Increased Risk with the Addition of Regional Radiotherapy?
40. PO-0725: Neoadjuvant PSA kinetics in prostate cancer with LHRH agonists: The importance of full testosterone suppression
41. A Multidisciplinary Rapid Access Clinic – Providing More Than Just Rapid Access
42. The Prevalence of Cardiac Risk Factors in Men With Localized Prostate Cancer Undergoing Androgren Deprivation Therapy in British Columbia, Canada
43. Treatment Patterns and Locoregional Recurrence Outcomes in Patients with pN0(i+) Breast Cancer
44. A comparison of surgical and radiotherapy breast cancer therapy utilization in Canada (British Columbia), Scotland (Dundee), and Australia (Western Australia) with models of “optimal” therapy
45. 10O_PR Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically-Defined Luminal A Breast Cancer
46. OC-0049 THE IMPACT OF COMORBIDITIES ON THE BENEFITS OF PROLONGED ANDROGEN ABLATION IN PATIENTS WITH T3-4 PROSTATE CANCER
47. Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?
48. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome
49. Population-based Validation of the Bolla Study in T3-4 Prostate Cancer in British Columbia
50. The Toxicity of Dose Escalated External Beam Radiation Therapy after Elective Pelvic Nodal Irradiation: Evaluating the Utility of the QUANTEC Rectal Dose Thresholds
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.